Provided by Tiger Trade Technology Pte. Ltd.

CSTONE PHARMA-B

5.140
0.000
Volume:- -
Turnover:- -
Market Cap:7.59B
PE:-71.92
High:5.140
Open:5.140
Low:5.140
Close:5.140
52wk High:13.150
52wk Low:2.030
Shares:1.48B
HK Float Shares:1.48B
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.071
ROE:-96.36%
ROA:-16.93%
PB:21.31
PE(LYR):-71.92
PS:33.16

Loading ...

CStone Pharmaceuticals (2616) Updates Joint Company Secretary Qualification and Announces Personnel Changes

Bulletin Express
·
Feb 06

CStone Pharmaceuticals-B Receives Exchange Approval for Company Secretary Qualification

Stock News
·
Feb 06

CStone Pharmaceuticals Appoints Weicong Ni as Sole Company Secretary

Reuters
·
Feb 06

BRIEF-Cstone Pharmaceuticals's CEO Buys Aggregate Of 976,000 Shares From Nov 2025 To Jan 2026

Reuters
·
Jan 27

CSTONE PHARMA-B (02616) CEO & Executive Director Dr. Yang Jianxin Purchases Additional 976,000 Shares, Cumulative Holdings Reach 12.477 Million Shares

Stock News
·
Jan 27

CStone Pharmaceuticals - CEO Buys Aggregate of 976,000 Shares From Nov 2025 to Jan 2026

THOMSON REUTERS
·
Jan 27

CStone Pharmaceuticals (SEHK:2616) Valuation After New Equity Awards And Board Changes

Simply Wall St.
·
Jan 26

CStone Pharmaceuticals (2616) Announces Grant of 15.72 Million Share Options and 8.06 Million RSUs

Bulletin Express
·
Jan 23

CSTONE PHARMA-B (02616) Grants 15.7155 Million Share Options and 8.055 Million Restricted Share Units

Stock News
·
Jan 23

CSTONE PHARMA-B (02616): Yan Jiaxun Appointed as Independent Non-Executive Director

Stock News
·
Jan 21

CStone Pharmaceuticals Files Director List with HKEX

Reuters
·
Jan 21

CStone Pharmaceuticals Appoints Catherine Yen as Independent Non-Executive Director

Reuters
·
Jan 21

Is CStone Pharmaceuticals (SEHK:2616) Turning Sugemalimab Data Into a Sustainable Immuno-Oncology Edge?

Simply Wall St.
·
Jan 13

CStone Pharmaceuticals-B (02616) Surges Over 6% in Intraday Trading as GIC Further Increases Stake, Ownership Exceeds 8%

Stock News
·
Jan 07

CSTONE PHARMA-B (02616) Receives Further Investment from GIC! Stake Rises to 8.06%

Stock News
·
Dec 30, 2025

GAVRETO’s NRDL Inclusion And China Alliance Network Might Change The Case For Investing In CStone Pharmaceuticals (SEHK:2616)

Simply Wall St.
·
Dec 21, 2025

CStone Pharmaceuticals (SEHK:2616): Valuation Check After GAVRETO Wins China National Reimbursement Drug List Approval

Simply Wall St.
·
Dec 15, 2025

Why CStone Pharmaceuticals (SEHK:2616) Is Up 7.9% After GAVRETO NRDL Inclusion Approval In China

Simply Wall St.
·
Dec 13, 2025

CStone Pharma-B (02616) Rises Over 5% as Pralsetinib Included in National Reimbursement List; Company Expands 2.0 Pipeline

Stock News
·
Dec 12, 2025

HK Movers | Biomedical Stocks Jump With Xuanzhu Biopharmaceutical up 22%

Tiger Newspress
·
Dec 12, 2025